JACC:外科瓣膜术后永久起搏器植入的危险因素研究

2019-11-20 不详 MedSci原创

需要永久起搏器(PPM)的心脏瓣膜手术后传导障碍的危险因素尚不清楚。本研究的目的旨在探究二尖瓣或主动脉瓣外科术后PPM植入的时间和危险因素。本研究纳入分析了77882名接受了二尖瓣或主动脉瓣外科手术的患者,主要终点事件是术后1年内的PPM植入。其中,有63.8%的患者接受了主动脉瓣置换术(AVR),18.9%患者接受了二尖瓣置换术(MVR),10.5%的患者接受了二尖瓣修复术(MVr),5.4%患

需要永久起搏器(PPM)的心脏瓣膜手术后传导障碍的危险因素尚不清楚。本研究的目的旨在探究二尖瓣或主动脉瓣外科术后PPM植入的时间和危险因素。

本研究纳入分析了77882名接受了二尖瓣或主动脉瓣外科手术的患者,主要终点事件是术后1年内的PPM植入。其中,有63.8%的患者接受了主动脉瓣置换术(AVR),18.9%患者接受了二尖瓣置换术(MVR),10.5%的患者接受了二尖瓣修复术(MVr),5.4%患者接受了主动脉瓣和二尖瓣置换术,1.4%患者接受了主动脉瓣置换术和二尖瓣修复术。MVr术后1年的PPM植入率为4.5%,AVR的为6.6%,AVR联合MVr的为9.3%,MVR的为10.5%,AVR联合MVR的为13.3%(p < 0.001)。MVr的PPM植入率最低,AVR联合MVR的植入率最高。高龄、心律失常病史、术前传导阻滞紊乱与PPM植入率风险增高相关。另外,术后超过30天后,慢性并发症与PPM植入风险增高相关。

研究结果显示,瓣膜手术后永久起搏器的植入仍是临床面临的一个问题,识别出PPM植入的风险因素可改善患者预后。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854575, encodeId=ee8218545e584, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Aug 16 14:44:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318852, encodeId=78291318852d2, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326401, encodeId=3e501326401a5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520634, encodeId=18ae152063481, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583636, encodeId=3a641583636b0, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2020-08-16 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854575, encodeId=ee8218545e584, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Aug 16 14:44:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318852, encodeId=78291318852d2, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326401, encodeId=3e501326401a5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520634, encodeId=18ae152063481, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583636, encodeId=3a641583636b0, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2019-11-22 HNYYM
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854575, encodeId=ee8218545e584, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Aug 16 14:44:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318852, encodeId=78291318852d2, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326401, encodeId=3e501326401a5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520634, encodeId=18ae152063481, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583636, encodeId=3a641583636b0, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854575, encodeId=ee8218545e584, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Aug 16 14:44:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318852, encodeId=78291318852d2, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326401, encodeId=3e501326401a5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520634, encodeId=18ae152063481, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583636, encodeId=3a641583636b0, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]
    2019-11-22 jiyangfei
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854575, encodeId=ee8218545e584, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sun Aug 16 14:44:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318852, encodeId=78291318852d2, content=<a href='/topic/show?id=bd0292e077b' target=_blank style='color:#2F92EE;'>#起搏器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92707, encryptionId=bd0292e077b, topicName=起搏器)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5494471, createdName=HNYYM, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326401, encodeId=3e501326401a5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520634, encodeId=18ae152063481, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583636, encodeId=3a641583636b0, content=<a href='/topic/show?id=508d68e698c' target=_blank style='color:#2F92EE;'>#瓣膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68769, encryptionId=508d68e698c, topicName=瓣膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58dc16986228, createdName=12498e5fm17(暂无昵称), createdTime=Fri Nov 22 07:44:00 CST 2019, time=2019-11-22, status=1, ipAttribution=)]

相关资讯

Heart:严重三尖瓣反流伴充血性心衰患者的预后分析

部分严重三尖瓣反流(TR)和充血性心衰(CHF)是接受药物治疗,而非手术治疗。本研究目的旨在比较和评估接受三尖瓣手术(TVS)和没有接受手术患者的临床特征和预后。本研究回顾分析了数据库中2556名严重TR患者,并排除接受心脏移植和没有充血性心衰的患者。最终,共纳入分析了534名严重TR和CHF患者,仅55名患者接受了TVS治疗。在479名没有接受手术治疗的患者中,有30%有手术指征。经过38个月的

JACC:ST段抬高型心梗患者应该选哪种冠脉支架?

目前,对于接受经皮冠脉介入治疗(PCI)的ST段抬高型心梗(STEMI)患者,尚无特异有效的药物洗脱支架(DES)被证实优于其他支架。本次荟萃分析研究的目的旨在比较和评估不同冠脉支架在STEMI患者中的安全性和有效性。 本研究回顾分析了来自15个随访时间超过12个月临床研究的10979名PCI患者(男性占77.3%,平均年龄为60.7岁),主要终点事件是心源性死亡、再梗死和靶血管血运重建的复

Nutri Metab Cardiovas:降低心衰风险、延长心血管疾病患者寿命,间歇性禁食益处多多!

导语:间歇性禁食最初因“网红减肥法”而被大家所熟知,近些年更因为其可改善类风湿性关节炎、多发性硬化症以及糖尿病患者的病情而备受热议。

JACC:他汀类药物的使用与认知力下降不呈相关性

他汀类药物可能与记忆和认知力下降相关,本研究的目的旨在评估老年患者他汀类药物使用和记忆与认知力变化的相关性。本研究纳入分析了MAS研究中的1037名70-90岁的患者,经过6年时间的随访,发现相比于从未使用他汀类药物的患者,他汀类药物使用者的记忆和认知力无明显差异,观察期间他汀类药物的启动与减缓记忆衰退的速度有关。探索性分析发现,使用他汀类药物与心脏病和载脂蛋白Eε4携带者的特异性记忆测试表现减弱

AHA 2019丨COLCOT试验:COLchicine心血管结局试验

2019年11月16日,一年一度的美国心脏协会科学年会(AHA)在美国宾夕法尼亚州费城隆重启幕,来自世界各地的15000多名顶尖医生、科学家、心脏病专家、保健专业人员和其他人士参加本次会议,讨论心血管科学和医学的未来。来自加拿大蒙特利尔心脏研究所的Jean-Claude Tardif教授在第一场LBS专场中为大家揭晓了COLCOT试验的最新研究结果,COLCOT试验的结果将确定,用小剂量消炎药秋水

Eur Heart J:Alirocumab对急性冠脉综合征患者心血管预后的影响

由此可见,在新近的ACS患者中,Alirocumab可改善患者结局,且与年龄无关。这表明降低LDL-C是ACS老年患者重要的预防干预措施。